

RELIABLE RESEARCH PARTNER WITH EXPERTISE, KNOW-HOW AND EXPERIENCE IN DRUG DISCOVERY FROM PLANT NATURAL PRODUCTS

Bi : coll

PRODUCTS

- Bicoll Plant **Profiles™** give you access to the most promising source for new patentable, high quality leads in 9 month at a reasonable cost. They can be applied both as pharmaceutical lead structures as well as in the field of nutraceutical / food additive.
- Custom synthesis from 1 mg to 1 kg in between 6 weeks and 3 months. Valuable partners such as Bayer, Boehringer Ingelheim and other research driven companies.
- EpicLeap database: Historical medicine applications at Charité provides the correlations between the historic drug prescriptions and treated diseases.

BICOLL IS LOOKING FOR PARTNERS

- who plans to bring small molecule drugs to the market
- with established screening test system (incl. animal test) who wants qualified drug candidates
- who wants to realize the fastest and most successful approach in drug discovery ready available

APPLICATION LINKS

Drug discovery: Most successful source: 80% TOP-200 Drugs >>

Orphan targets: From initial screening to animal data: 9-month >>

Rare diseases: German Patent 10 2005 027 796.9 >>

Screening: Isolation of Anti-HIV compounds >>

Lead generation: Synthesis of CRHR1 antagonist DMP696 >>

Lead optimization: US\$20 million EU funded project >>

Food additives: Natural product communications, **2015**, Vol. 10(4), 597- 603 >>

Potential partners

Pharma, academia and research institutes

Bicoll

Industry: Biotechnology
Employees: 40
Founded: 2000

Headquarters

Munich, Germany

Research Lab

Shanghai, China

COMPANY MISSION

INNOVATE AND ACCELERATE THE DEVELOPING PROCESS OF NEW DRUG CANDIDATES

Bi : coll

- 2000** Bicoll GmbH founded in Munich, Germany.
- 2001** Bicoll GmbH, Germany, opens its Sino part: Bicoll Biotechnology (Shanghai) Co. Ltd., P.R. China.
- 2002** Dr. Kai Lamottke has been appointed General Manager of Bicoll Biotechnology (Shanghai) Co. Ltd. (Shanghai).
- 2004** Bicoll GmbH has generated an after-tax profit in the last fiscal year, in its third year of operation. Company sells its research products to five strategic customers in the pharmaceutical industry and leading research institutions. Additionally, Bicoll follows up its own in-house development projects and builds up expertise with a new approach in the area of oncology.
- 2005** Bicoll (Shanghai) Co. Ltd. expands its laboratory facilities within Zhangjiang Hi-Tech Park/Shanghai.
- 2006** Ricerca Biosciences, LLC, USA and The Bicoll Group enter significant collaboration agreement.
- 2007** Bicoll announces the signing of a new partnership with Genfit and the partial financing of a 3.2 million euro joint EuroTrans-Bio project by ERA-Net/ European Commission.
- 2009** Bicoll and Genfit announce the identification of active compounds for inflammatory diseases – First candidates de-orphanize nuclear receptor in their joint project OLNORME.
- 2010** Bicoll and the European Molecular Biology Laboratory (EMBL) announce results of their joint research project on the identification of aurora kinase inhibitors.
- 2011** Innovative fragment library concept allows identification of new lead compounds for immediate pre-clinical use; Bicoll and Crelux to market co-developed new fragment service platform. Bicoll and Naturalpha extend Nutraceutical Research Alliance; European-Funded Research Cooperation OLNORME II.
- 2013** Bicoll as partner of a EUR 2.7 million. European-Funded EuroTrans-Bio Program; OLNORME II program focuses on the development of a new class of drug candidates for the prevention and treatment of cardio metabolic diseases with an inflammatory component. Bicoll receives first payment as member of the EUR 11.5 million EU funded EpimiRNA project to develop novel epilepsy therapeutics. Bicoll announced a fast small molecule ligand validation method for orphan targets.*
- 2014** 40.000 historic formulations as starting point for new drugs - research project EpicLeap receives partial funding from the German Federal Ministry of Education and Research.
- 2016** Bicoll moves in to the heart of the leading European biotech cluster. The biopharmaceutical company is now one of the 62 start-up companies in the Innovation Center for Biotechnology in Martinsried near Munich.


BICOLL BIOAVAILABLE AND POTENT NATURAL COMPOUNDS



Bi:coll

PROVIDING ACCESS TO PLANT NATURAL COMPOUND LIBRARIES¹

- Access to unique pool of endemic Asian plants (through research locations in Shanghai & Munich)
- Reproducible scientific survey, collection, and characterization of plant material
- Preparation of up to 192 Bicoll plant Profiles™ (fine fractions) from one plant organ
- Innovative separation technologies enable fast access to new structures and pure compounds



TECHNOLOGIES

BIFRAC N™ – Proprietary separation system to generate screening libraries

Bicoll plant **Profiles™** – Ready to use fine fractions (non-polar and polar) derived from plant extracts

BIPRESELECT™ – High throughput prediction toolbox to evaluate hits according to physico-chemical properties

¹E.g.: The Identification of Naturally Occurring Neuroscogenin as a Bioavailable, Potent and High-Affinity Agonist of the Nuclear Receptor ROR (NR1F1), S. Helleboid, C. Haug, K. Lamotte, Y. Zhou, J. Wei, S. Daix, L. Cambula, G. Rigou, D. W. Hum, R. Walczak, Journal of Biomolecular Screening, **2014**, 19, 399-406.



Dr. Kai Lamottke
Founder and CEO of
Bicoll Group

(picture middle)

Dr. Maria Lamottke
Chairman of the
Board of Directors,
Bicoll Biotechnology
(Shanghai) Co. Ltd.

(picture right)

Dr. Irene Meliciani
Business Consultant

(picture left)

InnoMuNiCH Project

PROJECT SET-UP EXAMPLE (COULD BE ADJUSTED TO THE NEEDS OF PARTNERS)

Example project name

„Development of screening tests using substance libraries of natural substances as fast validation starting point for the treatment of inflammation and arteriosclerosis: Determination of reactive oxygen species in connection with the activation of hit compounds“.

Rough financial plan

Period: 01.01.2018 - 31.12.2020
Total costs: 921.247,00 EUR
Funding support: 460.624,00 EUR
Own costs: 460.623,00 EUR

Total costs

0813 Materials 330.000,00 EUR
0837 Staff costs 456.247,00 EUR
0838 Business trips 15.000,00 EUR
0850 Other necessary costs 120.000,00 EUR

Co-financing strategy

Priority 1: Japanese partner is joining the project with own resources
Priority 2: Germany funding programs for further support
Priority 3: Own financing opportunities such as H2020, EU-Projects etc.

IP strategy

- If during the collaboration there will be developed a new method, technology, compound Bicoll is interested to patent it (alone or together).
- Depending on the project there could be other opportunities discussed.

**Get YOUR medicinal chemistry projects on fast track –
find OUR solutions for YOUR challenges:**

E-mail: contact@bicoll-group.com

Bicoll GmbH
Am Klopferspitz 19
82152 Planegg/Germany
Phone: +49 89 820 106 30
Fax: +49 89 529 178

Bicoll Biotechnology (Shanghai) Co. Ltd.
Research Laboratory
Bibo Road 518
Zhangjiang Hi-Tech Park Pudong
201203 Shanghai/China
Phone: +86 21 3895 3452
Fax: +86 21 3895 3271

www.bicoll-group.com